Research across Leukemia
Related studies from across the Leukemia family.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations
Scientists examine how sugar metabolism affects acute myeloid leukemia cells
This narrative review examines glycolytic enzymes and glycolytic metabolism within acute myeloid leukemia (AML) cells. The authors synthesiz…
This review looks at how glycolytic enzymes and metabolism impact acute myeloid leukemia cells, offering new insights into this serious bloo…
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia
Three FLT3 inhibitors show promise for AML patients
This network meta-analysis of 6128 acute myeloid leukemia patients compared FLT3 inhibitors. Gilteritinib and midostaurin improved complete …
Gilteritinib and midostaurin boost remission rates; gilteritinib and quizartinib improve survival in AML.
Genetic variants in ABCB1 and ABCG2 raise imatinib trough levels in CML patients
Genes affect imatinib drug levels in chronic myeloid leukemia patients
A meta-analysis shows specific ABCB1 and ABCG2 polymorphisms significantly increase imatinib plasma trough concentrations, supporting pharma…
Certain gene variants can raise imatinib levels in leukemia patients. This may help doctors personalize treatment for better results.
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
CPX-351 improves survival in AML with myelodysplasia-related changes
New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes
New AML Drug Shows Strong Response But Some Patients Face Higher Risk
This retrospective monocentric cohort study evaluated 60 consecutive patients treated with CPX-351 as first-line therapy for therapy-related…
A new leukemia drug helps most patients respond well, but those with high white blood cell counts or complex gene changes may face higher ri…